Aspergillosis in AIDS David W. Denning

Slides:



Advertisements
Similar presentations
Cardiovascular Side Effects of HIV Treatment
Advertisements

Discussion and analysis of the major trials in invasive aspergillosis David W. Denning Director, National Aspergillosis Centre University Hospital of South.
HIV-infection in Russia Alexander Panteleev Head of the HIV/TB department City TB Hospital # 2, St-Petersburg, Russia.
WHO – HIV department | February 21, |1 | November 2012 Core slides.
Global summary of the AIDS epidemic million [31.4 million–35.3 million] 30.8 million [29.2 million–32.6 million] 15.9 million [14.8 million–17.2.
Infections in non-myeloablative « Reduced intensity conditioning » stem cell transplant Catherine CORDONNIER Hôpital Henri Mondor, Créteil, France.
Diagnosis of pulmonary aspergillosis (ignoring allergy)
Epidemiology and surveillance of fungal infections: an overview
Chronic pulmonary aspergillosis
Aspergillus sinusitis
Azole resistance in Aspergillus – is it a problem? Dr Susan J Howard The University of Manchester & Regional Mycology Laboratory Manchester.
The extraordinary spectrum of diseases caused by Aspergillus
Fungal infections in COPD
Optimal Antifungal Prophylaxis The Case for Posaconazole Oliver A. Cornely, MD, FIDSA Dep. I for Internal Medicine Hematology - Oncology Infectious Diseases.
David W. Denning Wythenshawe Hospital University of Manchester
Chronic pulmonary aspergillosis
Clinical and radiological presentation and diagnosis
Neurological toxicity of Tri-azole Antifungals DR CAROLINE BAXTER Clinical Research Fellow
Is azole resistance increasing amongst Aspergillus species?
Postoperative aspergillosis Alessandro C. Pasqualotto School of Medicine, The University of Manchester Wythenshawe Hospital, UK.
Clinical failure and its management
Scottish Intensive Care Society Audit Group, Annual Report Note from Scottish Intensive Care Society Audit Group.
Core epidemiological slides HIV/AIDS estimates
November 2012 Core slides HIV/AIDS Epidemiology Health care response.
Definitions: Definitions: Obesity: Body Mass Index (BMI) of 30 or higher. Obesity: Body Mass Index (BMI) of 30 or higher. Body Mass Index (BMI): A measure.
The burden of invasive and serious fungal disease in the UK Denning DW 1, Pegorie M 2, Welfare W 2,3 24th European Congress of Clinical Microbiology and.
Asthma in Minnesota Slide Set Asthma Program Minnesota Department of Health January 2013.
Treatment of Fungal infections in Hematologic Malignancies
Trends in fungal disease in the UK Theresa Lamagni Healthcare-Associated Infection & Antimicrobial Resistance Department HPA Centre for Infections.
Source: CDC Behavioral Risk Factor Surveillance System Obesity Trends* Among U.S. Adults BRFSS, 1990, 1998, 2007 (*BMI 30, or about 30 lbs. overweight.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
Roswell Park Cancer Institute
Identification, Susceptibility & Resistance
Airborne fungi infections Dr David W. Denning FRCP FRCPath Scientific Advisor to the Fungal Research Trust Clinician, Wythenshawe Hospital Head, Antifungal.
Trends in fungal diseases Dr David W. Denning FRCP FRCPath Scientific Advisor to the Fungal Research Trust Clinician, Wythenshawe Hospital Head, Antifungal.
Discussion & Limitations Whereas the number of candidaemia cases and AIDS defining fungal infection in HIV patients are systematically surveyed, most fungal.
Initial Antifungal Therapy for Critical Ill Patients When and Which ? 林口長庚 胸腔內科 林鴻銓 Lin, Horng-Chyuan Division of Pulmonary Infectious & Immunological.
Antifungal management in the haematology patient
The extraordinary spectrum of diseases caused by Aspergillus David W. Denning Wythenshawe Hospital University of Manchester.
Conclusion Estimating the burden of fungal disease in Vietnam ResultsBackground Methods The prevalence of fungal infections in Vietnam is poorly described,
Interaction of Aspergillus with the host A unique microbial-host interaction Immune dysfunction Frequency of aspergillosis Immune hyperactivity Frequency.
Treatment of Aspergillosis John R. Perfect Duke University Medical Center.
Estimating the Burden of Serious Fungal Diseases in Thailand Methee Chayakulkeeree 1, David W. Denning 2* 1 Division of Infectious Diseases and Tropical.
Quorum Sensing in Pathogenic Burkholderias Aspergillus fumigatus and Invasive Aspergillosis Bill Nierman J. Craig Venter Institute Rockville, MD
Selection of an optimal antifungal for treatment of invasive aspergillosis: susceptibility/resistance, adverse reactions, drug interactions John Bennett,
Opportunistic Pathogens –Aspergillus species. Aspergillosis is an infection caused by Aspergillus, a common mold that lives indoors and outdoors. Most.
Maria N. Gamaletsou 1,2, David Denning 1, and Nikolaos V. Sipsas 2 1 The National Aspergillosis Centre, University Hospital of South Manchester and The.
THE BURDEN OF SERIOUS FUNGAL INFECTIONS IN VENEZUELA Maribel Dolande 1, María Mercedes Panizo 1, Giuseppe Ferrara 1, Víctor Alarcón 1, Nataly García 1,
OBJECTIVEMETHODSRESULTS BURDEN OF SERIOUS FUNGAL INFECTIONS IN SERBIA Valentina Arsic Arsenijevic 1, Sandra Sipetic Grujicic 2, Marina Pekmezovic 1, David.
The burden of serious fungal infections in Portugal Raquel Sabino 1, Cristina Verissímo C 1, Célia Pais 2, David W. Denning 3 1 Nacional Institute of Health.
Epidemiology: “The times, they are a changing..” Kieren A. Marr MD Director, Transplant and Oncology ID Johns Hopkins University School of Medicine.
* rate for adult females only An estimation of burden of serious fungal infections in France Jean-Pierre Gangneux 1, Marie-Elisabeth Bougnoux 2, Cendrine.
Hospital-acquired Invasive Aspergillosis: How Big is the Problem?
Timothy W. Felton, Caroline Baxter, Caroline B. Moore, Stephen A.Roberts, William W. Hope,and David W. Denning Clinical Infectious Diseases 2010; 51:1383–1391.
Fungal diseases in the UK
The National Aspergillosis Centre (NAC)
Estimated burden of fungal infections in Italy
Estimating serious fungal disease burden in the Philippines
Global Action Fund for Fungal Infections
Number of infections per underlying disorder per year
Dr Iain D Page NIHR Academic Clinical Lecturer in Infectious Diseases
8th Advances Against Aspergillosis international conference
Chronic Pulmonary Aspergillosis
8th Advances Against Aspergillosis international conference
Management of CPA Dr. Chris Kosmidis.
Allergic Bronchopulmonary Aspergillosis: Management
Management of Chronic Pulmonary Aspergillosis
Classification of allergic fungal disease in asthma.
Presentation transcript:

Aspergillosis in AIDS David W. Denning Director, National Aspergillosis Centre University Hospital South Manchester [Wythenshawe Hospital] The University of Manchester Myconostica Ltd

New manifestations of aspergillosis Aspergillosis in AIDS Denning et al, New Engl J Med 1991:324:654

Frequency

EU caseload of aspergillosis 167,500 ABPA cases 680,000 -1,700,000 SAFS cases 11,200,000 CFRS cases 30,000 - 70,000 cases Acute Invasive ABPA Severe asthma with fungal sensitisation Allergic sinusitis Subacute Invasive Frequency of aspergillosis Frequency of aspergillosis Aspergilloma Chronic cavitary Chronic fibrosing Locally invasive ~7,500 cases Immune dysfunction Immune hyperactivity . After Casadevall & Pirofski, Infect Immun 1999;67:3703

Trends over time in IFDs in AIDS – autopsy series 1630 autopsies in 2101 deaths (77.6%) IFD found in 297 (18.2%) IA was diagnosed during life in only 12% Antinori et al, Am J Clin Pathol 2009;132:221

CDC surveillance National survey in US 35,252 patients 1990 - 1998 IA diagnosed in 228 patients Incidence of 3.5/1000 person years Holding et al, Clin Infect Dis 2000;31:1253

Mumbai autopsy series Lanjewar & Duggal, HIV Med 2001;2:266

Risk factors

CDC surveillance Holding et al, Clin Infect Dis 2000;31:1253

Italian experience of aspergillosis in AIDS Libanore et al, Infection 2002;30:341

Risk factors for invasive aspergillosis in AIDS Stage of AIDS CDC Group II 4 (1%) CDC Group IV 289 (72%) Neutropenia <1000 x 106/L 92/202 (46%) Corticosteroid therapy 79/202 (39%) Prior pulmonary infection 124/169 (73%) Khoo & Denning, Clin Infect Dis 1994; 19 (S1) 541

Clinical suspicion

Missed IFDs in AIDS – autopsy series Antinori et al, Am J Clin Pathol 2009;132:221

Aspergillosis in AIDS Site of disease in 293 published cases Respiratory Other Sinuses 9 CNS 30 Otomastoiditis 5 Cardiac 10 Larynx 2 Renal 12 Tracheobronchitis 11 Thyroid 4 Obstructing bronchial 5 Miscellaneous 16 Invasive Pulmonary 208 Empyema/pleural mass 5 Aspergilloma 4 ≥ 2 organs involved = 47 Khoo & Denning, Clin Infect Dis 1994; 19 (S1) 541

Invasive pulmonary aspergillosis in AIDS Presenting features (in 78 patients) Cough 92 % Fever 91 % Dypsnoea 65 % Chest pain 24 % Haemoptysis 9 % Khoo & Denning, Clin Infect Dis 1994; 19 (S1) 541

Italian experience of aspergillosis in AIDS Libanore et al, Infection 2002;30:341

Invasive Pulmonary Aspergillosis in AIDS Patient JJ Late stage AIDS, unresponsive to ITZ (Af90 and Af91) Patient JB Denning et al, New Engl J Med 1991;324: 654

Invasive Pulmonary Aspergillosis, with dissemination, in AIDS Patient JA 31st May Patient JA 25th June, 3 days before death Denning et al, New Engl J Med 1991;324: 654

Invasive pulmonary aspergillosis in AIDS, showing nodules with cavitation WWW.aspergillus.org.uk

Invasive pulmonary aspergillosis in AIDS, showing upper lobe cavities Denning et al, New Engl J Med 1991;324: 654

Invasive pulmonary aspergillosis in AIDS Patient DF A. niger grown 5x from sputum WWW.aspergillus.org.uk;

Italian experience of aspergillosis in AIDS Libanore et al, Infection 2002;30:341

Radiology and diagnostic accuracy 8 radiologists compared with 8 internists 25 IPA and 25 other diagnoses in AIDS Analysed with and without clinical information Zaspel et al, Eur Radiol 2004;14: 2030

Radiology and diagnostic accuracy Zaspel et al, Eur Radiol 2004;14: 2030

Radiology and diagnostic accuracy AUC = 0.84 AUC = 0.75 Radiology and diagnostic accuracy Zaspel et al, Eur Radiol 2004;14: 2030

Obstructing bronchial aspergillosis Patient ML Pre-bronchscopy Patient ML After bronchoscopy Denning et al, New Engl J Med 1991;324: 654

Invasive Aspergillus tracheobronchitis in AIDS Lortholary et al, Am J Med 1993;95:177

Ear and sinus aspergillosis in AIDS Sinusitis Headache, facial, neck or ear pain; Nasal discharge Often chronic Invasive fungal otomastoiditis Ear pain (often severe), otorrhoea, without fever

Sphenoid sinusitis leading to local spread to the brain and cerebral aspergillosis Presented with headache over the vertex of the skull www.aspergillus.man.ac.uk

Establishing a diagnosis

Significance of positive respiratory cultures 45/972 (4.6%) incidence of positive cultures 5/45 (11%) invasive aspergillosis 4/13 (23%) neutropenic AIDS patients had invasive aspergillosis if positive sputum culture for Aspergillus Pursell et al. Clin Infect Dis 1992;14:141

Aspergillus in AIDS Species isolated (n = 82) A. fumigatus 69 (84%) A. flavus 7 (9%) A. niger 4 (5%) A. terreus 2 (2%) Khoo & Denning, Clin Infect Dis 1994; 19 (S1) 541

Early French experience of aspergillosis in AIDS “The mycologic culture from BAL was the method of choice for the diagnosis of invasive pulmonary disease” Of 28 patients with a positive BAL culture for Aspergillus, 15 underwent a biopsy or autopsy and 14 were positive at histology. Serum antigen detection was positive in only 4 of 16 tested patients. Lortholary et al, Am J Med 1993;95:177

Italian experience of aspergillosis in AIDS Libanore et al, Infection 2002;30:341

Would PCR help?

MycAssay™: Aspergillus MycAssay™: Pneumocystis Real-time molecular based in vitro diagnostic tests for Aspergillus spp. and Pneumocystis jirovecii Aspergillus based on 18S rRNA Pneumocystis based on mitochondrial LSU CE marked, but not FDA cleared 36

MycAssay™: Aspergillus Establishing a tentative clinical cut-off, for use in prospective regulatory studies 37

Treatment

Choice of antifungal for aspergillosis Priority sequence Voriconazole (unless drug interaction) AmBisome 3mg/Kg (if not ‘nephro-critical’) OR caspofungin/micafungin (if not neutropenic) 3. Posaconazole (oral only, if no drug interactions) 4. Itraconazole

When not to use voriconazole as primary therapy? Absolute contraindications Drug interactions (ie rifampicin, carbamazepine, phenytoin etc) Voriconazole used as prophylaxis (but not itraconazole or posaconazole) Resistance to voriconazole (esp zygomycosis, A. lentulus or azole resistance) Relative contraindications Renal failure (IV only) Young children (need higher dose ?+ other agent) Severe hepatic dysfunction Interacting drugs (ie sirolimus)

HIV therapy and azole interactions Beware!

IRIS

Immune reconstitution in invasive pulmonary aspergillosis, in AIDS Patient HB Day +14, CD4 cells 84/uL Patient HB Day +42, after AmB and ITZ Sambatakou, Eur J Clin Microbiol Infect Dis 2005;24:628

Immune reconstitution in invasive pulmonary aspergillosis, in AIDS Patient HB Day +64, CD4 cells 340/uL, on VRC Patient HB Day +87, day of death Sambatakou, Eur J Clin Microbiol Infect Dis 2005;24:628

Azole resistance

Chronic cavitary pulmonary aspergillosis (CCPA) in HIV February 2005 32 yr old from Malawi, on HAART Rx - haemoptysis - Aspergillus precipitin titre 1/16 CT scan shows 2 large cavities with aspergillomas, with additional lesions (October 2005) Surgical removal would require a pneumonectomy So treated with itraconazole

CCPA in HIV February 2007 On HAART Rx, with low viral load, CD4 count >200 - New haemoptysis - Aspergillus precipitin titre 1/32 CXR & CT scan showed expansion of inferior cavity MICs A. fumigatus Feb 2007 Itraconazole = >8.0mg/mL Voriconazole = 0.5 mg/mL Posaconazole = 1.0 mg/mL February 2007 April 2007

CCPA in HIV - low itraconazole concentrations Itraconazole concentrations Nov 05 2.5 mg/L Dec 05 3.4 mg/L March 06 4.5 mg/L July 06 6.7 mg/L Feb 07 8.4 mg/L Do low concentrations of antifungal predispose to the development of resistance?

Azole resistance in Manchester in A. fumigatus 11% 17% 7% 5% 0% 3% Howard et al, Emerg Infect Dis 2009;15:1068

www.aspergillus.org.uk

51